COMP <GO>
CAI vs ABBV // FREE CASH FLOW YIELD
Caris Life Sciences Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CAI 5
— ABBV 10
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $34.33 (-5.01%) • MKT CAP: $10.21B
fcf-yield
0.65%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 29.00% | -24.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.65% | 3.47% | -2.82 | ABBV | /fcf-yield <GO> |
| Operating Margin | 5.60% | 24.60% | -19.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 6.90% | -15.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 8.60% | +88.40 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 5.33 | +4.46 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 7.40% | -0.80 | CAI | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.8 | 72.8 | -10.00 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 1.15 | -0.24 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 113.1x | -92.10 | CAI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.21B | $513.86B | -$503.65B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | ABBV REV | CAI GROSS % | ABBV GROSS % | CAI FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $61.16B | 44.0% | 70.2% | $66.9M | $17.82B |
| FY 2024 | $412.3M | $56.33B | 44.0% | 70.0% | -$253.6M | $17.83B |
| FY 2023 | $306.1M | $54.32B | 44.0% | 44.0% | -$289.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
ABBV // BETA 1.15